Inactive Instrument

Company Delcath Systems, Inc. Nasdaq

Equities

US24661P5008

Medical Equipment, Supplies & Distribution

Business Summary

Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.

Sales per Business

USD in Million2022Weight2023Weight Delta
Hepzato Kit
100.0 %
3 100.0 % 2 100.0 % -18.96%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
3 100.0 % 2 100.0 % -18.96%

Managers

Managers TitleAgeSince
Chief Executive Officer 60 20-09-30
Director of Finance/CFO - 23-06-06
Compliance Officer - 22-01-24
Chief Tech/Sci/R&D Officer 60 12-03-18
Chief Operating Officer 53 Mar. 17
Chief Tech/Sci/R&D Officer 57 23-06-19

Members of the board

Members of the board TitleAgeSince
Director/Board Member 81 08-12-04
Chief Executive Officer 60 20-09-30
Director/Board Member 58 20-02-13
Director/Board Member 58 20-05-05
Director/Board Member 50 20-05-05
Chairman 60 19-07-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 22,922,728 22,187,223 ( 96.79 %) 0 96.79 %
Stock B 0 24,819 0 0

Shareholders

NameEquities%Valuation
AIGH Capital Management LLC
5.362 %
1,182,198 5.362 % 5 M $
Rosalind Advisors, Inc.
5.085 %
1,121,025 5.085 % 5 M $
Rosalind Advisors, Inc.
4.712 %
1,038,828 4.712 % 4 M $
BVF, Inc.
4.428 %
976,149 4.428 % 4 M $
BVP Partners LLC
4.315 %
951,258 4.315 % 4 M $
Vivo Capital LLC
3.879 %
855,191 3.879 % 4 M $
Vanguard Global Advisers LLC
2.368 %
522,008 2.368 % 2 M $
302,668 1.373 % 1 M $
Logos Global Management LP
1.361 %
300,000 1.361 % 1 M $
Worth Venture Partners LLC
1.335 %
294,248 1.335 % 1 M $
NameEquities%Valuation
BVP Partners LLC
45.28 %
4,358 45.28 % 18 173 $
Vivo Capital LLC
28.57 %
2,750 28.57 % 11 468 $
NameEquities%Valuation
Vivo Capital LLC
-
8,751 - 36 492 $
Stonepine Capital Management LLC
-
0 - - $
NameEquities%Valuation
Rosalind Advisors, Inc.
18.68 %
1,753 18.68 % 7 310 $
NameEquities%Valuation
Rosalind Advisors, Inc.
28.54 %
9,149 28.54 % 38 151 $

Company contact information

Delcath Systems, Inc.

566 Queensbury Avenue

12804, Queensbury

+212 489 2100

http://www.delcath.com
address Delcath Systems, Inc.